Organisation
Halia Therapeutics is a US firm leading an Alzheimer's therapy trial in Abu Dhabi
HT-4253 will be tested on Emiratis at risk of Alzheimer’s using data from the Emirati Genome Programme, marking a shift toward early‑stage intervention.
2 Jul 2026